355406-09-6
355406-09-6 structure
- Name: YM-155 (hydrochloride)
- Chemical Name: 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione,chloride
- CAS Number: 355406-09-6
- Molecular Formula: C20H19ClN4O3
- Molecular Weight: 398.84300
- Catalog: Signaling Pathways Apoptosis Survivin
- Create Date: 2016-12-05 00:35:32
- Modify Date: 2024-01-03 20:41:03
-
YM-155 hydrochloride is a novel survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.
| Name | 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione,chloride |
|---|---|
| Synonyms |
YM 155 hydrochloride
YM-155 hydrochloride||YM 155 hydrochloride CS-1150 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium chloride YM-155 (hydrochloride) |
| Description | YM-155 hydrochloride is a novel survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.54 nM (survivin) |
| In Vitro | YM155 (30 μM) is not sensitive to survivn gene promoter-driven luciferase reporter activity. YM155 shows significant supression on endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 via transcriptional inhibition of the survivin gene promoter. YM155 (100 nM) does not affect protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) such as PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50s ranging from 2.3 to 11 nM, respectively[1]. YM155 resultin in an increase in sensitivity of NSCLC cells to γ-radiation. YM155 combined with γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. In addition, YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA[2]. |
| In Vivo | YM155 (3 and 10 mg/kg) inhibits the tumor growth in PC-3 xenografts, without obvious body weight loss and blood cell count decrease. YM155 is highly distributed to tumor tissue in vivo. YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts[1]. YM155 in combination with γ-radiation shows potent antitumor activity against H460 or Calu6 xenografts in nude mice[2]. In this orthotopic renal and metastatic lung tumors models, YM155 and IL-2 additively decreases tumor weight, lung metastasis, and luciferin-stained tumor images[3]. |
| Kinase Assay | A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5'-GCGCGCTCGAGTCTAGACATGCGGATATATTC-3' and 5'-GCGCGAA-GCTTTGGCGGTTAATGGCGCGC-3'. The resulting PCR fragment is digested with XhoI/HindIII and ligated into the XhoI/HindIII cleavage site of the pGL3-Basic vector. The resulting plasmid is named pSUR-luc. DNA sequencing is done on all amplified sequences by a DNA sequencer. The activity of pSUR-luc is confirmed by luciferase assay with transiently transfected HeLa-S3 cells. Luciferase assay is done. The pGL3 control vector, which contains the SV40 promoter and enhancer sequences, is used. HeLa cells are stably transfected with pSUR-luc and pSV2bsr by Lipofect-AMINE 2000. After blasticidin selection at 10 μg/mL, a single colony is chosen based on appropriate luciferase signals and genetic stability over time and named HeLa-SURP-luc. CHO cells are stably transfected with pGL3-control and pSV2bsr. After blasticidin selection at 10 μg/mL, a single colony is chosen based on appropriate luciferase signals and genetic stability over time and named CHO-SV40-luc. Stocked cells from the HeLa-SURP-luc and CHO-SV40-luc clones are used for chemical screening and characterization of YM155. YM155 in DMSO are added to the cells, which had been seeded the previous day on 96-well plastic plates at 5×103 per well. Luciferase activity is measured 24 hours later. IC50 is calculated by logistic analysis. |
| Cell Assay | The antiproliferative activity of YM-155 is measured. After treatment with YM-155 for 48 h, the cell count is determined by sulforhodamine B assay. The GI50 value is calculated by logistic analysis, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by sulforhodamine B staining) in control cells during the drug incubation. The assay is done in triplicate, and the mean GI50 value is obtained from the results of four independent assays. |
| Animal Admin | Five-week-old male nude mice (BALB/c nu/nu) are used for the assay. PC-3 cells (2×106-3×106) are injected into the flanks of the mice and allowed to reach a tumor volume of > 100 mm3 in tumor volume (length×width2×0.5). YM-155 is s.c. administered as a 3-day continuous infusion per week for 2 weeks using an implanted micro-osmotic pump or i.v. administered five times a week for 2 weeks. The percentage of tumor growth inhibition 14 days after initial YM-155 administration is calculated for each group using the following formula: MTV=100×{1-[(MTV of the treated group on day 14)-(MTV of the treated group on day 0)]/[(MTV of the control group on day 14)-(MTV of the control group on day 0)]}, where MTV is mean tumor volume. For both the frozen tumors and plasma samples, survivin expression levels are analyzed by Western blotting and YM-155 drug concentration by high-performance liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) using validated methods. |
| References |
| Molecular Formula | C20H19ClN4O3 |
|---|---|
| Molecular Weight | 398.84300 |
| Exact Mass | 398.11500 |
| PSA | 77.96000 |
| Storage condition | 2-8℃ |
|
~%
355406-09-6 |
| Literature: Astellas Pharma Inc. Patent: EP1614686 A1, 2006 ; Location in patent: Page/Page column 5-6 ; |
| Precursor 1 | |
|---|---|
| DownStream 0 | |